Investors might want to bet on Incyte (INCY - Free Report) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.
Analysts' growing optimism on the earnings prospects of this specialty drugmaker is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Incyte, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate Revisions
The company is expected to earn $0.58 per share for the current quarter, which represents a year-over-year change of +45%.
Over the last 30 days, three estimates have moved higher for Incyte while three have gone lower. As a result, the Zacks Consensus Estimate has increased 8%.
Current-Year Estimate Revisions
For the full year, the earnings estimate of $2.75 per share represents a change of +164.42% from the year-ago number.
In terms of estimate revisions, the trend for the current year also appears quite encouraging for Incyte. Over the past month, eight estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 8.06%.
Favorable Zacks Rank
Thanks to promising estimate revisions, Incyte currently carries a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Incyte shares have added 12.9% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.